Science News
from research organizations

New Treatment Using Human Antibodies To Target Harmful Toxins May Protect Against C. Difficile

Date:
November 21, 2006
Source:
American Society For Microbiology
Summary:
A new therapeutic method using human antibodies to neutralize toxins was found to prevent Clostridium difficile-induced death in hamsters say researchers from New Jersey and Massachusetts. C. difficile is the leading cause of nosocomial antibiotic-associated diarrhea, often resulting from the administration of antibiotics such as clindamycin, ampicillin, or cephalosporins. C. difficile associated diarrhea (CDAD) effects approximately 300,000 patients per year in the U.S. alone.
Share:
       
FULL STORY

A new therapeutic method using human antibodies to neutralize toxins was found to prevent Clostridium difficile-induced death in hamsters say researchers from New Jersey and Massachusetts. They report their findings in the November 2006 issue of the journal Infection and Immunity.

C. difficile is the leading cause of nosocomial antibiotic-associated diarrhea, often resulting from the administration of antibiotics such as clindamycin, ampicillin, or cephalosporins. C. difficile associated diarrhea (CDAD) effects approximately 300,000 patients per year in the U.S. alone. Treatment available to date includes discontinuation of the antibiotic causing the illness as well as administration of medication such as metronidazole or vancomycin. Although both methods offer initial relief, there is currently a 10 to 20% relapse rate among patients. Due to the recent emergence of more virulent C. difficile strains, in addition to increasing vancomycin resistance, researchers are focusing on new treatments and relapse prevention therapy.

In the study mice were used to isolate human monoclonal antibodies (HuMAbs) capable of neutralizing C. difficile toxins A and B. Researchers then tested anti-toxin A HuMAb CDA1 alone and in conjunction with anti-toxin B HUMAb MDX-1388 for the ability to protect hamsters from C.difficle-induced death and relapse prevention. Results showed that combination therapy reduced mortality from 100% to 45% in the primary disease model and from 78% to 32% in the relapse model.

"These human and animal studies, taken together, demonstrate the relevance of toxin-reactive antibodies in disease outcomes," say the researchers. "Here we describe the characterization of a panel of neutralizing, fully human monoclonal antibodies (HuMAbs) directed against either toxin A or toxin B. HuMAb CDA1 (against toxin A) alone could protect hamsters from mortality, but significantly enhanced protection was observed when the antibodies were administered as a combination therapy."

(G.J. Babcock, T.J. Broering, H.J. Hernandez, R.B. Mandell, K. Donahue, N. Boatright, A.M. Stack, I. Lowy, R. Graziano, D. Molrine, D.M. Ambrosino, W.D. Thomas, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infection and Immunity, 74. 11: 6339-6347.)


Story Source:

The above post is reprinted from materials provided by American Society For Microbiology. Note: Materials may be edited for content and length.


Cite This Page:

American Society For Microbiology. "New Treatment Using Human Antibodies To Target Harmful Toxins May Protect Against C. Difficile." ScienceDaily. ScienceDaily, 21 November 2006. <www.sciencedaily.com/releases/2006/11/061120055742.htm>.
American Society For Microbiology. (2006, November 21). New Treatment Using Human Antibodies To Target Harmful Toxins May Protect Against C. Difficile. ScienceDaily. Retrieved August 3, 2015 from www.sciencedaily.com/releases/2006/11/061120055742.htm
American Society For Microbiology. "New Treatment Using Human Antibodies To Target Harmful Toxins May Protect Against C. Difficile." ScienceDaily. www.sciencedaily.com/releases/2006/11/061120055742.htm (accessed August 3, 2015).

Share This Page: